{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:36:58Z","timestamp":1784191018417,"version":"3.55.0"},"reference-count":29,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1997,2,1]]},"abstract":"<jats:p>A change in the recommendations for routine immunization of children is indicated because of the reduced risk of exposure to wild-type polio viruses and the continued occurrence of vaccine-associated paralytic poliomyelitis after oral polio vaccine (OPV). All children should receive four doses of vaccine before the child enters school. Regimens of sequential inactivated polio vaccine (IPV) and OPV, IPV only, or OPV only are acceptable. Each regimen has advantages and disadvantages. In special circumstances, one of the regimens is preferred or recommended. Because logistical problems with the current childhood immunization schedule may make these new recommendations difficult to implement immediately, their adoption likely will be gradual. Nevertheless, assuming continued progress toward global eradication and the development of new combination products, the routine use of an IPV-only regimen is likely to become desirable and feasible in future years.<\/jats:p>","DOI":"10.1542\/peds.99.2.300","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:40:17Z","timestamp":1092440417000},"page":"300-305","source":"Crossref","is-referenced-by-count":34,"title":["Poliomyelitis Prevention: Recommendations for Use of Inactivated Poliovirus Vaccine and Live Oral Poliovirus Vaccine"],"prefix":"10.1542","volume":"99","author":[{"name":"Committee on Infectious Diseases","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[1997,2,1]]},"reference":[{"key":"2021121006473396100_B1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/clinids\/14.2.568","article-title":"Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease.","volume":"14","author":"Strebel","year":"1992","journal-title":"Clin Infect Dis."},{"key":"2021121006473396100_B2","first-page":"681","article-title":"Update. Eradication of paralytic poliomyelitis in the Americas.","volume":"41","author":"Centers for Disease Control and Prevention","year":"1992","journal-title":"MMWR."},{"key":"2021121006473396100_B3","first-page":"720","article-title":"Certification of poliomyelitis eradication\u2014the Americas, 1994.","volume":"43","author":"Centers for Disease Control and Prevention","year":"1994","journal-title":"MMWR."},{"key":"2021121006473396100_B4","first-page":"345","article-title":"Expanded programme on immunization: statement on poliomyelitis eradication.","volume":"70","author":"World Health Organization","year":"1995","journal-title":"Weekly Epidemiol Record."},{"key":"2021121006473396100_B5","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)90111-6","article-title":"To conquer poliomyelitis forever.","volume":"345","author":"Cochi","year":"1995","journal-title":"Lancet."},{"key":"2021121006473396100_B6"},{"key":"2021121006473396100_B7"},{"key":"2021121006473396100_B8"},{"key":"2021121006473396100_B9","first-page":"13","article-title":"Red Book Committee considers increased IPV use.","volume":"10","author":"Peter","year":"1995","journal-title":"AAP News."},{"key":"2021121006473396100_B10","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1542\/peds.94.5.774","article-title":"Administration of the third dose of oral poliomyelitis vaccine at 6 to 18 months of age.","volume":"94","author":"Committee on Infectious Diseases, American Academy of Pediatrics","year":"1994","journal-title":"Pediatrics."},{"key":"2021121006473396100_B11","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/jama.1996.03530450029028","article-title":"Seroprevalence of antibody against poliovirus in inner-city preschool children.","volume":"275","author":"Chen","year":"1996","journal-title":"JAMA."},{"key":"2021121006473396100_B12"},{"key":"2021121006473396100_B13"},{"key":"2021121006473396100_B14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-3476(94)70307-8","article-title":"Epidemiology of Guillain-Barre\u0301 E9 syndrome in children: relationship of oral polio vaccine administration to occurrence.","volume":"124","author":"Rantala","year":"1994","journal-title":"J Pediatr."},{"key":"2021121006473396100_B15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/archpedi.1994.02170050037007","article-title":"Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991: implications for estimating the risk of vaccine-associated disease.","volume":"148","author":"Prevots","year":"1994","journal-title":"Arch Pediatr Adolesc Med."},{"key":"2021121006473396100_B16"},{"key":"2021121006473396100_B17"},{"key":"2021121006473396100_B18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.aje.a115009","article-title":"Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines.","volume":"128","author":"McBean","year":"1988","journal-title":"Am J Epidemiol."},{"key":"2021121006473396100_B19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/infdis\/162.6.1291","article-title":"Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses.","volume":"162","author":"Faden","year":"1990","journal-title":"J Infect Dis."},{"key":"2021121006473396100_B20"},{"key":"2021121006473396100_B21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/infdis\/168.2.452","article-title":"Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccine.","volume":"168","author":"Faden","year":"1993","journal-title":"J Infect Dis."},{"key":"2021121006473396100_B22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/00365548709117192","article-title":"A study of sero-immunity that has protected the Swedish population against poliomyelitis for 25 years.","volume":"19","author":"Bottiger","year":"1987","journal-title":"Scand J Infect Dis."},{"key":"2021121006473396100_B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/163.1.1","article-title":"Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines.","volume":"163","author":"Onorato","year":"1991","journal-title":"J Infect Dis."},{"key":"2021121006473396100_B24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00006454-199510000-00003","article-title":"Inactivated polio vaccine for the United States: a missed vaccination opportunity.","volume":"14","author":"Plotkin","year":"1995","journal-title":"Pediatr Infect Dis J."},{"key":"2021121006473396100_B25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/00006454-198710000-00001","article-title":"Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States.","volume":"6","author":"McBean","year":"1987","journal-title":"Pediatr Infect Dis J."},{"key":"2021121006473396100_B26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/infdis\/168.5.1105","article-title":"Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine.","volume":"168","author":"Abraham","year":"1993","journal-title":"J Infect Dis."},{"key":"2021121006473396100_B27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/infdis\/164.1.191","article-title":"Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines.","volume":"164","author":"Ogra","year":"1991","journal-title":"J Infect Dis."},{"key":"2021121006473396100_B28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0264-410X(95)00211-I","article-title":"Inactivated poliovirus vaccine: past and present experience.","volume":"14","author":"Murdin","year":"1996","journal-title":"Vaccine."},{"key":"2021121006473396100_B29"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/99\/2\/300\/987420\/pe029700300o.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/99\/2\/300\/987420\/pe029700300o.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T15:37:33Z","timestamp":1639150653000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/99\/2\/300\/64705\/Poliomyelitis-Prevention-Recommendations-for-Use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,2,1]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[1997,2,1]]},"published-print":{"date-parts":[[1997,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.99.2.300","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[1997,2,1]]}}}